



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HBV-IN-45

Cat. No.:	HY-163516
Molecular Formula:	C ₁₆ H ₁₆ N ₂ O ₂ S
Molecular Weight:	300.38
Target:	HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC ₅₀ of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities ^[1] .
In Vitro	HBV-IN-45 (compound 26f) inhibits the growth of HepG2 cells with a CC ₅₀ values of 84.29 μM. HBV-IN-45 also inhibits HBV DNA in HepAD38 cell supernatant with an EC ₅₀ of 2.24 μM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	HBV-IN-45 (compound 26f; 100 mg/kg; oral administration; twice daily; for 14 days) inhibits HBV DNA copy numbers in plasma, and the HBeAg and liver enzymes GPT (ALT) in mouse serum have no difference ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	Male BALB/c mice injected with replication-competent HBV 1.3 DNA plasmid ^[1]
Dosage:	100 mg/kg
Administration:	Oral administration; twice daily; for 14 days
Result:	HBV DNA copy numbers were rapidly and markedly reduced in plasma.

REFERENCES

[1]. Kaixin Du, et al. Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection. Eur J Med Chem. 2024 Apr 16;271:116402.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA